Breaking News Instant updates and real-time market news.

KRA

Kraton

$37.22 /

-0.09 (-0.24%)

 16:46
02/17/21
 02/17
16:46
 02/17/21
16:46

Kraton announces global price hike for pine chemicals, AMS products

Kraton Corporation announced a general price increase of 10% across its entire Pine Chemicals and AMS portfolio. Subject to the terms of any applicable contracts and obligations this price increase will be effective immediately.

  • 25

    Feb

KRA Kraton
$37.22 /

-0.09 (-0.24%)

10/19/20 Truist
Truist raises price targets in select Chemicals names
10/16/20 Loop Capital
Kraton price target raised to $45 from $29 at Loop Capital
10/09/20 Truist
Kraton price target raised to $30 from $25 at Truist
10/06/20 Truist
Kraton price target raised to $25 from $20 at Truist

TODAY'S FREE FLY STORIES

Upgrade
Altair upgraded to Neutral from Sell at Goldman Sachs » 16:57
03/01/21
03/01
16:57
03/01/21
16:57
ALTR

Altair

$63.27 /

+1.72 (+2.79%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALTR Altair
$63.27 /

+1.72 (+2.79%)

02/24/21
Altair acquires Flow Simulator sofftware from GE Aviation
01/19/21
Altair signs MoU with Rolls-Royce Germany
01/05/21
Toggled, Yorkland Controls collaborate for intelligent lighting solutions
12/08/20
Altair CFO Howard Morof to step down, Matthew Brown to succeed
ALTR Altair
$63.27 /

+1.72 (+2.79%)

02/19/21 RBC Capital
Altair price target raised to $58 from $49 at RBC Capital
12/09/20 JPMorgan
Altair upgraded to Overweight from Neutral at JPMorgan
12/08/20 Benchmark
Altair price target raised to $60 from $53 at Benchmark
11/09/20 RBC Capital
Altair price target raised to $49 from $42 at RBC Capital
ALTR Altair
$63.27 /

+1.72 (+2.79%)

02/25/21
Altair sees FY21 revenue $423M-$431M, consensus $486.22M
02/25/21
Altair sees Q1 revenue $138M-$140M, consensus $134.72M
02/25/21
Altair reports Q4 EPS 17c, consensus 0c
12/08/20
Altair reaffirms Q4, FY20 guidance
ALTR Altair
$63.27 /

+1.72 (+2.79%)

02/22/21
Fly Insider: Corvus, ALJ Regional Holdings among week's notable insider trades
12/09/20
JPMorgan downgrades Zoom, upgrades Autodesk in software ratings shakeup
Syndicate
RedHill Biopharma announces $10M bought deal offering of ADSs » 16:55
03/01/21
03/01
16:55
03/01/21
16:55
RDHL

RedHill Biopharma

$9.19 /

-0.33 (-3.47%)

RedHill Biopharma…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RDHL RedHill Biopharma
$9.19 /

-0.33 (-3.47%)

02/23/21
RedHill Biopharma to expand opaganib global Phase 2/3 COVID-19 study
01/29/21
RedHill Biopharma announces independent DSMB recommendation for opaganib
01/06/21
RedHill Biopharma's RHB-204 granted FDA Fast Track designation for NTM disease
12/31/20
RedHill Biopharma announces safety, efficacy data from Phase 2 COVID-19 study
RDHL RedHill Biopharma
$9.19 /

-0.33 (-3.47%)

11/12/20 Roth Capital
RedHill Biopharma price target lowered to $12 from $16 at Roth Capital
09/11/20 BTIG
RedHill Biopharma initiated with a Buy at BTIG
08/14/20 Roth Capital
Roth Capital maintains Buy on RedHill after 'noisy' quarter
07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
RDHL RedHill Biopharma
$9.19 /

-0.33 (-3.47%)

11/12/20
RedHill Biopharma reports Q3 EPS (5c), consenus (16c)
Syndicate
Yum China files to sell 2.1M shares of common stock  16:53
03/01/21
03/01
16:53
03/01/21
16:53
YUMC

Yum China

$59.87 /

+0.095 (+0.16%)

 
ShowHide Related Items >><<
YUMC Yum China
$59.87 /

+0.095 (+0.16%)

02/05/21
Yum China named official supplier of Asian Games Hangzhou 2022
02/03/21
Yum China sees 'significant headwinds' in Q1
02/03/21
Yum China reports Q4 restaurant margin 15.1% vs. 12.4% a year ago
02/03/21
Yum China sees FY21 CapEx approximately $600M
YUMC Yum China
$59.87 /

+0.095 (+0.16%)

01/26/21 Jefferies
Yum China price target raised to $68.70 from $63.10 at Jefferies
11/02/20 Citi
Yum China price target raised to $71.30 from $60.15 at Citi
09/10/20 Goldman Sachs
Yum China H-shares initiated with a Conviction Buy at Goldman Sachs
09/10/20 Goldman Sachs
Yum China H-shares initiated with a Conviction Buy at Goldman Sachs
YUMC Yum China
$59.87 /

+0.095 (+0.16%)

02/03/21
Yum China reports Q4 adjusted EPS 35, consensus 26c
10/28/20
Yum China reports Q3 adjusted EPS 66c, consensus 49c
10/28/20
Notable companies reporting after market close
  • 04
    Sep
YUMC Yum China
$59.87 /

+0.095 (+0.16%)

09/04/20
Yum China to raise more than $2B in Hong Kong listing, FT reports
YUMC Yum China
$59.87 /

+0.095 (+0.16%)

02/03/21
Fly Intel: After-Hours Movers
09/10/20
Fly Intel: Pre-market Movers
Earnings
AppFolio reports Q4 EPS (1c), consensus 7c » 16:52
03/01/21
03/01
16:52
03/01/21
16:52
APPF

AppFolio

$160.72 /

-4.985 (-3.01%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APPF AppFolio
$160.72 /

-4.985 (-3.01%)

09/08/20
AppFolio sells MyCase to Apax Partners fund for $193M
APPF AppFolio
$160.72 /

-4.985 (-3.01%)

02/25/21 DA Davidson
AppFolio price target raised to $126 from $110 at DA Davidson
01/25/21 Stephens
AppFolio initiated with an Underweight at Stephens
01/25/21 Stephens
AppFolio initiated with an Underweight at Stephens
10/26/20 Keefe Bruyette
AppFolio initiated with a Market Perform at Keefe Bruyette
APPF AppFolio
$160.72 /

-4.985 (-3.01%)

11/09/20
AppFolio reports Q3 EPS $3.86 vs. 14c last year
16:30 Today
AppFolio - APPF
Earnings
Adverum Biotechnologies reports Q4 EPS (39c), consensus (32c) » 16:50
03/01/21
03/01
16:50
03/01/21
16:50
ADVM

Adverum Biotechnologies

$13.29 /

+0.44 (+3.42%)

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADVM Adverum Biotechnologies
$13.29 /

+0.44 (+3.42%)

16:47 Today
Adverum Biotechnologies provides update on ADVM-022 clinical development path
02/22/21
Adverum appoints Reed Tuckson to board of directors
02/02/21
Adverum announces publication of safety data on ADVM-022 gene therapy
01/11/21
Adverum Biotechnologies announces 2021 focus areas
ADVM Adverum Biotechnologies
$13.29 /

+0.44 (+3.42%)

12/15/20 UBS
Adverum Biotechnologies initiated with a Neutral at UBS
11/15/20 Piper Sandler
Adverum Biotechnologies shares should grind higher over time, says Piper Sandler
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform from Underperform at Raymond James
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform at Raymond James
ADVM Adverum Biotechnologies
$13.29 /

+0.44 (+3.42%)

11/05/20
Adverum Biotechnologies reports Q3 EPS (31c), consensus (34c)
  • 13
    Aug
03/08/21
Biopharmaceuticals
16:30 Today
Adverum Biotechnologies - ADVM
Hot Stocks
Adverum Biotechnologies provides update on ADVM-022 clinical development path » 16:47
03/01/21
03/01
16:47
03/01/21
16:47
ADVM

Adverum Biotechnologies

$13.29 /

+0.44 (+3.42%)

Adverum Biotechnologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADVM Adverum Biotechnologies
$13.29 /

+0.44 (+3.42%)

02/22/21
Adverum appoints Reed Tuckson to board of directors
02/02/21
Adverum announces publication of safety data on ADVM-022 gene therapy
01/11/21
Adverum Biotechnologies announces 2021 focus areas
01/11/21
Adverum Biotechnologies completes patient enrollment for INFINITY Phase 2 trial
ADVM Adverum Biotechnologies
$13.29 /

+0.44 (+3.42%)

12/15/20 UBS
Adverum Biotechnologies initiated with a Neutral at UBS
11/15/20 Piper Sandler
Adverum Biotechnologies shares should grind higher over time, says Piper Sandler
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform from Underperform at Raymond James
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform at Raymond James
ADVM Adverum Biotechnologies
$13.29 /

+0.44 (+3.42%)

11/05/20
Adverum Biotechnologies reports Q3 EPS (31c), consensus (34c)
  • 13
    Aug
03/08/21
Biopharmaceuticals
16:30 Today
Adverum Biotechnologies - ADVM
On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:45
03/01/21
03/01
16:45
03/01/21
16:45
JNJ

Johnson & Johnson

$159.34 /

+0.92 (+0.58%)

, XOM

Exxon Mobil

$56.40 /

+2.02 (+3.71%)

, OTRK

Ontrak

$31.62 /

-27.515 (-46.53%)

, ATNX

Athenex

$5.47 /

-6.715 (-55.11%)

, DKNG

DraftKings

$68.71 /

+7.24 (+11.78%)

, MORF

Morphic

$84.57 /

+48.64 (+135.37%)

The three major averages…

Open Full Text

ShowHide Related Items >><<
JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

02/28/21
Fly Intel: Top five weekend stock stories
02/28/21
CDC Advisory Committee recommends J&J single-shot COVID vaccine for adults 18+
02/27/21
Johnson & Johnson Covid vaccine granted emergency approval from FDA
02/26/21
J&J confirms FDA panel recommends COVID-19 vaccine for EUA
XOM Exxon Mobil
$56.40 /

+2.02 (+3.71%)

08:47 Today
Michael Angelakis and Jeffrey Ubben join ExxonMobil board
02/24/21
Exxon Mobil to sell U.K. upstream central and northern North Sea assets
02/16/21
Paulson & Co. buys Exxon, exits Qiagen in Q4
02/12/21
Exxon Mobil targets cash operating expense reduction of $6B by FY23
OTRK Ontrak
$31.62 /

-27.515 (-46.53%)

10/29/20
Ontrak acquires behavior change platform LifeDojo
10/13/20
Ontrak rises after announcing launch of Ontrak-CI program
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

07:35 Today
Athenex trading resumes
07:22 Today
Athenex expects cash to fund operations into 2Q22
07:21 Today
Athenex announces key anticipated future milestones
07:08 Today
FDA requests new study from Athenex for oral paclitaxel plus encequidar
DKNG DraftKings
$68.71 /

+7.24 (+11.78%)

02/26/21
DraftKings MUPs for B2C segment up 44% vs. 4Q19
02/25/21
Bill introduced in Florida Senate to authorize sports wagering
02/25/21
Nevada reports January statewide gaming win down 26.6% to $761.85M
02/25/21
DraftKings names Cal Ripken Jr. as special advisor to board of directors
MORF Morphic
$84.57 /

+48.64 (+135.37%)

09:52 Today
Morphic Holding Inc trading resumes
09:47 Today
Morphic Holding Inc trading halted, volatility trading pause
07:26 Today
Morphic Holding reports interim results from Phase 1 trial of MORF-057
01/05/21
Morphic Therapeutic expands R&D collaboration with Janssen
JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
XOM Exxon Mobil
$56.40 /

+2.02 (+3.71%)

02/26/21 Barclays
Exxon Mobil price target raised to $65 from $59 at Barclays
02/16/21 Credit Suisse
Exxon Mobil price target raised to $62 from $52 at Credit Suisse
02/08/21
Fly Intel: Top five analyst upgrades
02/08/21 Exane BNP Paribas
Exxon Mobil upgraded to Neutral from Underperform at Exane BNP Paribas
OTRK Ontrak
$31.62 /

-27.515 (-46.53%)

10:21 Today RBC Capital
RBC downgrades Ontrak to Sector Perform, cuts target to $32 after loss of Aetna
10:17 Today RBC Capital
Ontrak downgraded to Sector Perform from Outperform at RBC Capital
01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
01/04/21 B. Riley Securities
Ontrak price target raised to $110 from $100 at B. Riley Securities
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

16:38 Today JPMorgan
JPMorgan downgrades Athenex on 'huge surprise' from FDA
16:31 Today SVB Leerink
Athenex downgraded to Market Perform from Outperform at SVB Leerink
16:27 Today JPMorgan
Athenex downgraded to Neutral from Overweight at JPMorgan
13:53 Today Laidlaw
Athenex price target lowered to $13 from $38 at Laidlaw
DKNG DraftKings
$68.71 /

+7.24 (+11.78%)

09:18 Today Craig-Hallum
DraftKings price target raised to $70 from $65 at Craig-Hallum
09:09 Today Canaccord
DraftKings price target raised to $80 from $65 at Canaccord
08:39 Today Northland
DraftKings price target raised to $70 from $55 at Northland
07:05 Today Benchmark
DraftKings price target raised to $69 from $66 at Benchmark
MORF Morphic
$84.57 /

+48.64 (+135.37%)

12:48 Today Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

01/26/21
Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45
01/26/21
Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82
01/25/21
Notable companies reporting before tomorrow's open
01/25/21
Notable companies reporting before tomorrow's open
XOM Exxon Mobil
$56.40 /

+2.02 (+3.71%)

02/02/21
Exxon Mobil reports Q4 ex-items EPS 3c, consensus 1c
02/01/21
Notable companies reporting before tomorrow's open
02/01/21
Notable companies reporting before tomorrow's open
12/30/20
Exxon Mobil says Q4 income boosted by up to $600M from gas prices
OTRK Ontrak
$31.62 /

-27.515 (-46.53%)

08:07 Today
Ontrak sees FY21 revenue $100M, consensus $165.05M
08:06 Today
Ontrak reports Q4 EPS (7c), consensus (30c)
11/05/20
Ontrak reports Q3 EPS (36c), consensus (35c)
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

07:21 Today
Athenex reports Q4 adjusted EPS (43c), consensus (44c)
11/05/20
Athenex sees 2020 y-o-y product sales growth in low twenties percentage growth
11/05/20
Athenex reports Q3 EPS (44c), consensus (43c)
DKNG DraftKings
$68.71 /

+7.24 (+11.78%)

02/26/21
DraftKings raises 2021 revenue view to $900M-$1B from $750M-$850M
02/26/21
DraftKings reports Q4 revenue $322M, consensus $232.6M
02/25/21
Notable companies reporting before tomorrow's open
02/25/21
Notable companies reporting before tomorrow's open
MORF Morphic
$84.57 /

+48.64 (+135.37%)

12:53 Today
Morphic Holding reports 2020 EPS ($1.47), consensus ($1.41)
11/09/20
Morphic Holding reports Q3 EPS 17c, consensus (48c)
  • 07
    Oct
  • 10
    Sep
  • 19
    Jun
JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

02/26/21
FDA panel says J&J COVID-19 vaccine benefits outweigh risks, CNBC says
02/26/21
FDA advisory panel to review J&J's Covid-19 vaccine Friday, WSJ reports
02/25/21
Johnson & Johnson one-dose COVID-19 vaccine approved by Bahrain, Reuters says
02/24/21
FDA to release detailed review of J&J's Covid vaccine, WSJ reports
XOM Exxon Mobil
$56.40 /

+2.02 (+3.71%)

08:22 Today
Ubben, Angelakis to join board of Exxon Mobil, CNBC reports
02/17/21
Texas prohibits natgas firms from taking fuel out of state, Bloomberg says
02/17/21
Saudis to raise oil output as prices recover, WSJ reports
02/05/21
Exxon considering nominating Jeff Ubben to board, CNBC reports
DKNG DraftKings
$68.71 /

+7.24 (+11.78%)

02/12/21
Nevada to roll back capacity restrictions on casinos, Reno Gazette Journal says
02/09/21
TX Lt. Gov. sees no support for legalized sports betting, Houston Chronicle says
01/28/21
DraftKings to bring sportsbook, casino apps to Google Play, 9to5Google says
01/28/21
DraftKings sportsbook, casino apps soon available via Google Play, Reuters says
JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

12:23 Today
Fly Intel: Wall Street's top stories at midday
09:15 Today
Fly Intel: Pre-market Movers
02/24/21
Fly Intel: Wall Street's top stories for Wednesday
02/24/21
Fly Intel: Wall Street's top stories at midday
XOM Exxon Mobil
$56.40 /

+2.02 (+3.71%)

12:23 Today
Fly Intel: Wall Street's top stories at midday
09:15 Today
Fly Intel: Pre-market Movers
02/02/21
Fly Intel: Wall Street's top stories for Tuesday
02/02/21
Fly Intel: Wall Street's top stories at midday
OTRK Ontrak
$31.62 /

-27.515 (-46.53%)

12:23 Today
Fly Intel: Wall Street's top stories at midday
11:12 Today
Ontrak plunges after announcing loss of Aetna contract
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

12:23 Today
Fly Intel: Wall Street's top stories at midday
09:15 Today
Fly Intel: Pre-market Movers
12/15/20
Fly Intel: Pre-market Movers
09/21/20
Fly Insider: Kingsway Financial, Nvidia among week's notable insider trades
DKNG DraftKings
$68.71 /

+7.24 (+11.78%)

02/26/21
Fly Intel: Wall Street's top stories for Friday
02/26/21
Bet On It: Florida and Texas trying to get in on the action
02/26/21
Fly Intel: Wall Street's top stories at midday
02/26/21
Fly Intel: Pre-market Movers
MORF Morphic
$84.57 /

+48.64 (+135.37%)

12:23 Today
Fly Intel: Wall Street's top stories at midday
03/05/21
Medical Technology
03/08/21
Biopharmaceuticals
00:00 Today
26th Annual Energy Virtual Summit
03/02/21
41st Annual Healthcare Virtual Conference
08:00 Today
Athenex - ATNX
08:00 Today
Morphic Holding - MORF
03/09/21
Ontrak - OTRK
04/20/21
Johnson & Johnson - JNJ
03/03/21
Exxon Mobil Corp.
03/09/21
DraftKings Inc
JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

09:40 Today
Unusually active option classes on open March 1st
01/26/21
Early notable gainers among liquid option names on January 26th
12/01/20
Johnson & Johnson call volume above normal and directionally bullish
10/13/20
Unusually active option classes on open October 13th
XOM Exxon Mobil
$56.40 /

+2.02 (+3.71%)

09:40 Today
Unusually active option classes on open March 1st
02/09/21
Unusually active option classes on open February 9th
02/08/21
Exxon Mobil call volume above normal and directionally bullish
02/08/21
Unusually active option classes on open February 8th
OTRK Ontrak
$31.62 /

-27.515 (-46.53%)

10/12/20
Largest borrow rate increases among liquid names
09/16/20
Ontrak put volume heavy and directionally bearish
09/15/20
Ontrak put volume heavy and directionally bearish
DKNG DraftKings
$68.71 /

+7.24 (+11.78%)

02/02/21
DraftKings call volume above normal and directionally bullish
01/27/21
DraftKings call volume above normal and directionally bullish
01/26/21
DraftKings call volume above normal and directionally bullish
01/12/21
DraftKings call volume above normal and directionally bullish
Hot Stocks
Ormat Technologies calls Hindenburg Research comments 'misleading' » 16:44
03/01/21
03/01
16:44
03/01/21
16:44
ORA

Ormat Technologies

$84.64 /

-0.96 (-1.12%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ORA Ormat Technologies
$84.64 /

-0.96 (-1.12%)

02/24/21
Ormat Technologies increases quarterly dividend by 9% to 12c per share
11/12/20
Ormat Technologies resumes operation of Puna Geothermal Power Plant
10/01/20
Ormat Technologies expands energy storage footprint in California
09/23/20
Ormat Technologies VP Krieger buys 3,000 shares of company stock
ORA Ormat Technologies
$84.64 /

-0.96 (-1.12%)

02/02/21 Roth Capital
Ormat Technologies price target raised to $100 from $70 at Roth Capital
01/20/21 JPMorgan
Ormat Technologies price target raised to $94 from $86 at JPMorgan
01/06/21 JPMorgan
Ormat downgraded to Neutral on valuation at JPMorgan
01/06/21 JPMorgan
Ormat Technologies downgraded to Neutral from Overweight at JPMorgan
ORA Ormat Technologies
$84.64 /

-0.96 (-1.12%)

02/24/21
Ormat Technologies sees FY21 revenue $640M-$675M, consensus $707.04M
02/24/21
Ormat Technologies reports Q4 adjusted EPS 39c, consensus 34c
11/03/20
Ormat cuts FY20 revenue view to $707M-$717M from $710M-$725M
11/03/20
Ormat Technologies reports Q3 EPS 31c, consensus 27c
  • 19
    Nov
ORA Ormat Technologies
$84.64 /

-0.96 (-1.12%)

11/16/20
Fly Intel: After-Hours Movers
11/03/20
Fly Intel: After-Hours Movers
Syndicate
Knoll files to sell 10.68M shares of common stock for holders  16:44
03/01/21
03/01
16:44
03/01/21
16:44
KNL

Knoll

$16.99 /

+0.59 (+3.60%)

 
ShowHide Related Items >><<
KNL Knoll
$16.99 /

+0.59 (+3.60%)

10/27/20
Knoll falls -13.1%
10/16/20
Knoll appoints Jeffrey Henderson to board of directors
09/17/20
Furniture makers jump after Herman Miller earnings helped by 'home office' trend
09/17/20
Knoll rises 15.8%
KNL Knoll
$16.99 /

+0.59 (+3.60%)

02/10/21
Knoll reports Q4 EPS 14c, consensus 27c
Hot Stocks
Bottomline Technologies Bottomline appoints Bruce Bowden CFO » 16:43
03/01/21
03/01
16:43
03/01/21
16:43
EPAY

Bottomline Technologies

$44.39 /

-0.44 (-0.98%)

Bottomline announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EPAY Bottomline Technologies
$44.39 /

-0.44 (-0.98%)

08/07/20 RBC Capital
Bottomline Technologies price target raised to $57 from $51 at RBC Capital
05/19/20 Citi
Bottomline Technologies price target raised to $49 from $46 at Citi
05/08/20 Raymond James
Bottomline Technologies price target lowered to $51 from $66 at Raymond James
05/07/20 Craig-Hallum
Bottomline Technologies price target lowered to $53 from $68 at Craig-Hallum
EPAY Bottomline Technologies
$44.39 /

-0.44 (-0.98%)

02/02/21
Bottomline Technologies sees FY21 EPS $1.13-$1.17, consensus $1.21
02/02/21
Bottomline Technologies sees Q3 EPS 25c-27c, consensus 30c
02/02/21
Bottomline Technologies reports Q2 EPS 30c, consensus 28c
11/05/20
Bottomline Technologies sees Q2 EPS 27c-28c, consensus 31c
EPAY Bottomline Technologies
$44.39 /

-0.44 (-0.98%)

11/05/20
Fly Intel: After-Hours Movers
Earnings
Idera Pharmaceuticals reports Q4 ex-items EPS (22c), consensus (23c) » 16:42
03/01/21
03/01
16:42
03/01/21
16:42
IDRA

Idera Pharmaceuticals

$4.90 /

+0.55 (+12.64%)

As of December 31, 2020,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IDRA Idera Pharmaceuticals
$4.90 /

+0.55 (+12.64%)

11/17/20
Idera Pharmaceuticals appoints Dan Soland COO
09/28/20
Idera Pharmaceuticals announces patent coverage for tilsotolimod
09/15/20
Idera Pharmaceuticals to present tilsotolimod data at ESMO Virtual Congress
IDRA Idera Pharmaceuticals
$4.90 /

+0.55 (+12.64%)

11/02/20 JPMorgan
Idera Pharmaceuticals assumed with an Overweight at JPMorgan
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
IDRA Idera Pharmaceuticals
$4.90 /

+0.55 (+12.64%)

10/29/20
Idera Pharmaceuticals reports Q3 EPS (59c), consensus (22c)
Conference/Events
UBS technology analyst to hold an analyst/industry conference call » 16:42
03/01/21
03/01
16:42
03/01/21
16:42

Technology Analyst Arcuri…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Syndicate
BioCryst files automatic mixed securities shelf  16:42
03/01/21
03/01
16:42
03/01/21
16:42
BCRX

BioCryst

$11.97 /

+1.175 (+10.88%)

 
ShowHide Related Items >><<
BCRX BioCryst
$11.97 /

+1.175 (+10.88%)

02/25/21
BioCryst not providing specific revenue or operating expense guidance
02/03/21
BioCryst announces FDA approval of supplemental NDA for RAPIVAB
02/02/21
BioCryst reports inducement grants under Nasdaq listing rule
02/01/21
BioCryst jumps after WallStreetBets user says 'most undervalued' in market
BCRX BioCryst
$11.97 /

+1.175 (+10.88%)

07:37 Today Cowen
Cowen starts BioCryst at Outperform with $16 price target
07:03 Today Cowen
BioCryst initiated with an Outperform at Cowen
02/26/21 Barclays
BioCryst price target raised to $13 from $9 at Barclays
02/25/21 Piper Sandler
BioCryst's U.S. launch of Orladeyo now underway, says Piper Sandler
BCRX BioCryst
$11.97 /

+1.175 (+10.88%)

02/25/21
BioCryst reports Q4 EPS (34c), consensus (25c)
11/05/20
BioCryst reports Q3 EPS (26c), consensus (25c)
  • 28
    May
BCRX BioCryst
$11.97 /

+1.175 (+10.88%)

02/01/21
WallStreetBets tells CBS 'large amount' of stock content coming from bots
BCRX BioCryst
$11.97 /

+1.175 (+10.88%)

01/25/21
Fly Intel: After-Hours Movers
12/04/20
Fly Intel: Pre-market Movers
10/22/20
Fly Intel: Pre-market Movers
09/30/20
Fly Intel: Wall Street's top stories for Wednesday
03/02/21
41st Annual Healthcare Virtual Conference
BCRX BioCryst
$11.97 /

+1.175 (+10.88%)

02/19/21
BioCryst call volume above normal and directionally bullish
02/12/21
BioCryst call volume above normal and directionally bullish
01/15/21
BioCryst call volume above normal and directionally bullish
12/04/20
Unusually active option classes on open December 4th
Syndicate
Gamida Cell files to sell 6.33M ordinary shares for holders  16:41
03/01/21
03/01
16:41
03/01/21
16:41
GMDA

Gamida Cell

$9.86 /

+0.46 (+4.89%)

 
ShowHide Related Items >><<
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

02/09/21
Gamida Cell says phase 3 results show faster hematopoietic recovery
01/11/21
Gamida Cell to present full data from Phase 3 study of omidubicel at TCT meeting
12/14/20
FDA asks Gamida Cell for more manufacturing-related data for pre-BLA
12/09/20
Gamida Cell provides achieves all three secondary endpoints of omidubicel study
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

02/10/21 H.C. Wainwright
Gamida Cell price target raised to $27 from $15 at H.C. Wainwright
02/09/21 Piper Sandler
Gamida Cell price target raised to $25 from $13 at Piper Sandler
12/14/20 Oppenheimer
Gamida Cell price target lowered to $17 from $20 at Oppenheimer
12/14/20 Piper Sandler
Gamida Cell delay does not impact peak sales, says Piper Sandler
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

11/10/20
Gamida Cell reports Q3 EPS (30c), consensus (31c)
  • 19
    May
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

02/10/21
Fly Intel: Wall Street's top stories for Wednesday
02/10/21
Fly Intel: Wall Street's top stories at midday
02/10/21
Fly Intel: Pre-market Movers
12/07/20
Fly Intel: Wall Street's top stories for Monday
GMDA Gamida Cell
$9.86 /

+0.46 (+4.89%)

01/19/21
Nine new option listings and thirteen option delistings on January 19th
Earnings
Aziyo Biologics sees FY21 revenue $50M-$52M, consensus $50.81M » 16:41
03/01/21
03/01
16:41
03/01/21
16:41
AZYO

Aziyo Biologics

$15.26 /

-0.205 (-1.33%)

"While COVID-19…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

02/17/21
Aziyo Biologics announces first patient enrolled in HEAL study
11/16/20
Surgalign, Aziyo Biologics update distribution pact
09/28/20
Aziyo Biologics appoints Matthew Ferguson CFO
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

11/19/20 Piper Sandler
Aziyo Biologics posted 'nice revenue beat' in Q3, says Piper Sandler
11/02/20 Truist
Aziyo Biologics initiated with a Buy at Truist
11/02/20 Truist
Aziyo Biologics initiated with a Buy at Truist
11/02/20 Cowen
Aziyo Biologics initiated with an Outperform at Cowen
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

16:39 Today
Aziyo Biologics reports Q4 EPS (57c), consensus (50c)
11/19/20
Aziyo Biologics reports Q3 EPS ($15.79), consensus ($3.42)
  • 08
    Oct
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

10/11/20
Opening Day: iHuman makes trading debut amid U.S.-China tensions
03/02/21
41st Annual Healthcare Virtual Conference
16:30 Today
Aziyo Biologics - AZYO
03/17/21
Aziyo Biologics
03/18/21
Aziyo Biologics
Earnings
Aziyo Biologics reports Q4 EPS (57c), consensus (50c) » 16:39
03/01/21
03/01
16:39
03/01/21
16:39
AZYO

Aziyo Biologics

$15.26 /

-0.205 (-1.33%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

02/17/21
Aziyo Biologics announces first patient enrolled in HEAL study
11/16/20
Surgalign, Aziyo Biologics update distribution pact
09/28/20
Aziyo Biologics appoints Matthew Ferguson CFO
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

11/19/20 Piper Sandler
Aziyo Biologics posted 'nice revenue beat' in Q3, says Piper Sandler
11/02/20 Truist
Aziyo Biologics initiated with a Buy at Truist
11/02/20 Truist
Aziyo Biologics initiated with a Buy at Truist
11/02/20 Cowen
Aziyo Biologics initiated with an Outperform at Cowen
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

11/19/20
Aziyo Biologics reports Q3 EPS ($15.79), consensus ($3.42)
  • 08
    Oct
AZYO Aziyo Biologics
$15.26 /

-0.205 (-1.33%)

10/11/20
Opening Day: iHuman makes trading debut amid U.S.-China tensions
03/02/21
41st Annual Healthcare Virtual Conference
16:30 Today
Aziyo Biologics - AZYO
03/17/21
Aziyo Biologics
03/18/21
Aziyo Biologics
Syndicate
Editas Medicine files automatic mixed securities shelf  16:39
03/01/21
03/01
16:39
03/01/21
16:39
EDIT

Editas Medicine

$46.91 /

+3.08 (+7.03%)

 
ShowHide Related Items >><<
EDIT Editas Medicine
$46.91 /

+3.08 (+7.03%)

02/08/21
Editas Medicine appoints James Mullen as CEO
01/11/21
Editas Medicine Chief Scientific Officer Charles Albright, Ph.D to step down
01/11/21
Editas Medicine says FDA clears initiation of EDIT-301 clinical trial
12/21/20
Editas leads gene editing stocks higher with 46% rally to $95.42
EDIT Editas Medicine
$46.91 /

+3.08 (+7.03%)

06:26 Today Barclays
Editas Medicine downgraded to Equal Weight from Overweight at Barclays
02/26/21 Truist
Editas Medicine downgraded to Hold from Buy at Truist
02/26/21 Truist
Editas Medicine downgraded to Hold from Buy at Truist
02/25/21 JPMorgan
JPMorgan cuts Editas Medicine to Underweight after 'uneventful' Q4 update
EDIT Editas Medicine
$46.91 /

+3.08 (+7.03%)

02/25/21
Editas Medicine reports Q4 EPS ($1.00), consensus (74c)
11/05/20
Editas Medicine reports Q3 EPS 12c, consensus (64c)
  • 21
    Jan
  • 24
    Jun
EDIT Editas Medicine
$46.91 /

+3.08 (+7.03%)

01/11/21
Fly Intel: Wall Street's top stories for Monday
01/11/21
Fly Intel: Wall Street's top stories at midday
12/10/20
Fly Intel: Pre-market Movers
12/09/20
Fly Intel: After-Hours Movers
EDIT Editas Medicine
$46.91 /

+3.08 (+7.03%)

12/21/20
Editas Medicine call volume above normal and directionally bullish
12/17/20
Largest borrow rate increases among liquid names
12/14/20
Editas Medicine call volume above normal and directionally bullish
10/30/20
Largest borrow rate increases among liquid names
Earnings
Gaia reports Q4 EPS 2c, consensus 0c » 16:39
03/01/21
03/01
16:39
03/01/21
16:39
GAIA

Gaia

$10.53 /

+0.795 (+8.17%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GAIA Gaia
$10.53 /

+0.795 (+8.17%)

09/09/20
Gaia says 'on track' for 30,000 net member additions in Q3
09/09/20
Gaia closes on sale of part of corporate HQ, reduces debt by $13M
GAIA Gaia
$10.53 /

+0.795 (+8.17%)

11/10/20 Lake Street
Gaia price target raised to $18 from $15 at Lake Street
06/10/20 B. Riley FBR
Gaia can re-rate meaningfully over next year, says B. Riley FBR
05/15/20 B. Riley FBR
Gaia shares offer 'significant re-rating' potential, says B. Riley FBR
04/28/20 Lake Street
Gaia Q1 in line when excluding live events, says Lake Street
GAIA Gaia
$10.53 /

+0.795 (+8.17%)

11/09/20
Gaia reports Q3 ex-items EPS 1c, consensus (4c)
03/15/21
33rd Annual Roth Virtual Conference
16:30 Today
Gaia - GAIA
Earnings
C3.ai reports Q3 EPS (13c), consensus (16c) » 16:39
03/01/21
03/01
16:39
03/01/21
16:39
AI

C3.ai

$120.78 /

+8.41 (+7.48%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AI C3.ai
$120.78 /

+8.41 (+7.48%)

02/25/21
C3.ai awarded omnibus U.S. patent for end-to-end enterprise AI platform
02/01/21
Shell, C3, Baker Hughes, Microsoft launch Open AI Energy Initiative
12/31/20
C3.ai falls -5.9%
12/30/20
C3.ai rises 5.6%
AI C3.ai
$120.78 /

+8.41 (+7.48%)

01/04/21 KeyBanc
C3.ai initiated with a Sector Weight at KeyBanc
01/04/21 Wedbush
Wedbush bullish on C3.ai, initiates with an Outperform
01/04/21 Canaccord
C3.ai initiated with a Hold at Canaccord
01/04/21 Morgan Stanley
C3.ai initiated with an Underweight at Morgan Stanley
AI C3.ai
$120.78 /

+8.41 (+7.48%)

02/16/21
Tiger Global bought DoorDash and 1Life during Q4, sold out of Alphabet
  • 09
    Dec
AI C3.ai
$120.78 /

+8.41 (+7.48%)

01/04/21
Fly Intel: Pre-market Movers
12/13/20
Opening Day: Airbnb shares double in IPO, DoorDash soars in debut
09/23/20
Fly Intel: After-Hours Movers
00:00 Today
Technology Virtual Conference 2021
17:00 Today
C3.ai - AI
AI C3.ai
$120.78 /

+8.41 (+7.48%)

02/09/21
C3 AI call volume above normal and directionally bullish
02/02/21
C3 AI call volume above normal and directionally bullish
01/06/21
Largest borrow rate increases among liquid names
12/15/20
Two new option listings on December 15th
Syndicate
WillScot announces offering of 10.75M shares of common stock for holders » 16:39
03/01/21
03/01
16:39
03/01/21
16:39
WSC

WillScot Mobile Mini

$27.76 /

+0.05 (+0.18%)

WillScot Mobile Mini…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WSC WillScot Mobile Mini
$27.76 /

+0.05 (+0.18%)

02/16/21
Cooperman's Omega Advisors buys GM, exits Lee in Q4
WSC WillScot Mobile Mini
$27.76 /

+0.05 (+0.18%)

02/02/21 Deutsche Bank
WillScot Mobile Mini price target raised to $26 from $22 at Deutsche Bank
01/26/21 DA Davidson
WillScot Mobile Mini price target raised to $30 from $25 at DA Davidson
01/13/21 Oppenheimer
WillScot Mobile Mini price target raised to $29 from $24 at Oppenheimer
11/10/20 Barclays
WillScot Mobile Mini reinstated with an Equal Weight at Barclays
WSC WillScot Mobile Mini
$27.76 /

+0.05 (+0.18%)

02/25/21
WillScot Mobile Mini sees FY21 revenue $1.7B-$1.8B, consensus $1.71B
02/25/21
WillScot Mobile Mini reports Q4 revenue $437.65M, consensus $421.14M
11/05/20
WillScot Mobile Mini sees FY20 revenue $1.32B-$1.37B, down from $1.32B-$.42B
11/05/20
WillScot Mobile Mini reports Q3 EPS 7c, consensus 7c
WSC WillScot Mobile Mini
$27.76 /

+0.05 (+0.18%)

10/21/20
WillScot Mobile Mini pitched as long idea by Dendur's Mac Levine
05/18/21
WillScot Mobile Mini
Conference/Events
UBS pulp & paper analyst to hold analyst/industry conference call » 16:38
03/01/21
03/01
16:38
03/01/21
16:38

Basic Materials Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Downgrade
JPMorgan downgrades Athenex on 'huge surprise' from FDA » 16:38
03/01/21
03/01
16:38
03/01/21
16:38
ATNX

Athenex

$5.47 /

-6.715 (-55.11%)

JPMorgan analyst Ling…

JPMorgan analyst Ling Wang downgraded Athenex to Neutral from Overweight with a price target of $7, down from $30. The stock closed Monday down 55%, or $6.64, to $5.46. The Complete Response Letter from the FDA in relation to the Oraxol filing in metastatic breast Cancer is a "huge surprise," Wang tells investors in a research note. The analyst is "very puzzled and disappointed" with the outcome and awaits further clarity upon management's meeting with the FDA. The setback opens up downside risk in the shares "due to a lack of clear near-term key value driver," says Wang. The analyst is concerned that the stock move may not wait till there is "full visibility."

ShowHide Related Items >><<
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

07:35 Today
Athenex trading resumes
07:22 Today
Athenex expects cash to fund operations into 2Q22
07:21 Today
Athenex announces key anticipated future milestones
07:08 Today
FDA requests new study from Athenex for oral paclitaxel plus encequidar
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

16:31 Today SVB Leerink
Athenex downgraded to Market Perform from Outperform at SVB Leerink
16:27 Today JPMorgan
Athenex downgraded to Neutral from Overweight at JPMorgan
13:53 Today Laidlaw
Athenex price target lowered to $13 from $38 at Laidlaw
13:48 Today Needham
Athenex downgraded to Hold from Buy at Needham
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

07:21 Today
Athenex reports Q4 adjusted EPS (43c), consensus (44c)
11/05/20
Athenex sees 2020 y-o-y product sales growth in low twenties percentage growth
11/05/20
Athenex reports Q3 EPS (44c), consensus (43c)
  • 10
    Sep
ATNX Athenex
$5.47 /

-6.715 (-55.11%)

12:23 Today
Fly Intel: Wall Street's top stories at midday
09:15 Today
Fly Intel: Pre-market Movers
12/15/20
Fly Intel: Pre-market Movers
09/21/20
Fly Insider: Kingsway Financial, Nvidia among week's notable insider trades
08:00 Today
Athenex - ATNX
Hot Stocks
UFP Industries unit UBEECO buys Australia's Gilmores » 16:37
03/01/21
03/01
16:37
03/01/21
16:37
UFPI

UFP Industries

$63.04 /

+1.955 (+3.20%)

UFP Industries announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UFPI UFP Industries
$63.04 /

+1.955 (+3.20%)

02/22/21
UFP Industries unit buys Spartanburg Forest Products assets for $17M
02/01/21
UFP Industries increases quarterly dividend 20% to 15c per share
01/04/21
UFP Industries gets initial payment from sale of interest in PalletOne
12/10/20
Equus II Inc announces pending sale of PalletOne equity for $232M
UFPI UFP Industries
$63.04 /

+1.955 (+3.20%)

02/25/21 DA Davidson
UFP Industries price target raised to $75 from $67 at DA Davidson
10/26/20 Benchmark
UFP Industries price target raised to $74, named Top Pick at Benchmark
07/27/20 BMO Capital
UFP Industries price target raised to $53 from $44 at BMO Capital
06/18/20 Benchmark
UFP Industries price target raised to $56 from $50 at Benchmark
UFPI UFP Industries
$63.04 /

+1.955 (+3.20%)

02/24/21
UFP Industries reports Q4 EPS $1.02, consensus 73c
10/21/20
UFP Industries reports Q3 EPS $1.25, consensus 89c
Initiation
Fulcrum Therapeutics initiated with a Buy at Stifel » 16:37
03/01/21
03/01
16:37
03/01/21
16:37
FULC

Fulcrum Therapeutics

$12.92 /

+0.37 (+2.95%)

Stifel analyst Dae Gon Ha…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$12.92 /

+0.37 (+2.95%)

12/14/20
X4 Pharmaceuticals appoints Diego Cadavid as CMO
12/09/20
Fulcrum Therapeutics to host KOL event on FTX-6058 for sickle cell disease
12/06/20
Fulcrum Therapeutics presents updated data on SCD program
11/10/20
Fulcrum Therapeutics: Curtis Oltmans to join as general counsel
FULC Fulcrum Therapeutics
$12.92 /

+0.37 (+2.95%)

10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
08/12/20 Morgan Stanley
Fulcrum Therapeutics downgraded at Morgan Stanley, price target slashed to $11
FULC Fulcrum Therapeutics
$12.92 /

+0.37 (+2.95%)

11/10/20
Fulcrum Therapeutics reports Q3 EPS (70c), consensus (65c)
  • 20
    Jan
03/04/21
Fulcrum Therapeutics - FULC
Hot Stocks
SP Plus selected to provide parking management, shuttle operations at STL » 16:36
03/01/21
03/01
16:36
03/01/21
16:36
SP

SP Plus

$34.19 /

+1.01 (+3.04%)

SP Plus announced its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SP SP Plus
$34.19 /

+1.01 (+3.04%)

11/15/20
Fly Intel: Top five weekend stock stories
10/12/20
SP Plus appoints Colleen Kozak as CHRO
10/01/20
SP Plus commences with plan to install new 'touchless' equipment at LRD
SP SP Plus
$34.19 /

+1.01 (+3.04%)

02/22/21 Barrington
SP Plus price target raised to $39 from $36 at Barrington
11/19/20 Barrington
SP Plus price target raised to $36 from $29 at Barrington
05/11/20 Barrington
SP Plus price target lowered to $36 from $51 at Barrington
SP SP Plus
$34.19 /

+1.01 (+3.04%)

02/17/21
SP Plus reports Q4 EPS 2c, consensus 16c
11/05/20
SP Plus sees generating positive free cash flow rest of this year, into 2021
11/05/20
SP Plus reports Q3 adjusted EPS 62c, consensus (34c)
SP SP Plus
$34.19 /

+1.01 (+3.04%)

11/14/20
Wintrust Financial, AtlasAir Worldwide worth a look, Barron's says
SP SP Plus
$34.19 /

+1.01 (+3.04%)

02/17/21
Fly Intel: After-Hours Movers

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.